A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Sponsor

M.D. Anderson Cancer Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT05268003

Collaborator

(none)

Enrollment

Location

Arms

51.9

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia

Condition or Disease	Intervention/Treatment	Phase
Acute Lymphoblastic Leukemia Leukemia	Drug: Ponatinib Drug: Venetoclax Drug: Mini-hyper CVD	Phase 2

Detailed Description

OBJECTIVES

The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

Primary Objective:

To assess complete remission (CR) / CR with incomplete count recovery (CRi) rate with the combination of Ponatinib and mini-hyper-CVD chemotherapy and venetoclax.

Secondary Objectives:

To assess the safety of the regimen To assess rate of measurable residual disease (MRD) negative remission To assess duration of response (DOR), progression-free survival (PFS) and overall survival (OS)

Exploratory Objectives:

To assess the level of phospho-LCK in pretreatment samples and correlation with the To assess expression of BCL-2 family proteins

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

Actual Study Start Date :

Jun 7, 2022

Anticipated Primary Completion Date :

Oct 5, 2026

Anticipated Study Completion Date :

Oct 5, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ponatinib Patients will continue to take ponatinib 30mg daily continuously daily from Day 1. On Day 1, 20mg for 1 day, 50mg for 1 day, 100mg for 1 day, 200mg for 1 day, then 400mg daily	Drug: Ponatinib 30mg daily
Experimental: Venetoclax Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.	Drug: Venetoclax 400mg daily
Experimental: Mini-hyper-CVD Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.	Drug: Mini-hyper CVD 8 cycles of dose intensive therapy

Arm

Intervention/Treatment

Experimental: Ponatinib

Patients will continue to take ponatinib 30mg daily continuously daily from Day 1. On Day 1, 20mg for 1 day, 50mg for 1 day, 100mg for 1 day, 200mg for 1 day, then 400mg daily

Drug: Ponatinib

30mg daily

Experimental: Venetoclax

Patients will continue venetoclax 400mg daily on days 1-14 of each 28-day cycle.

Drug: Venetoclax

400mg daily

Experimental: Mini-hyper-CVD

Chemotherapy will be administered in the inpatient setting, starting on day 1 of each of the cycles 2-8.

Drug: Mini-hyper CVD

8 cycles of dose intensive therapy

Outcome Measures

Primary Outcome Measures

To determine the complete remission (CR) / CR with incomplete count recovery (CRi) rate with the combination of Ponatinib and mini-hyper-CVD chemotherapy and venetoclax. [through study completion, an average of 1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with relapsed or refractory T-cell acute lymphoblastic leukemia defined as receiving one or more cytotoxic containing regimens and A. Bone marrow involvement with ≥ 5% lymphoblasts B. Age ≥ 18 Years
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Adequate organ function

Serum total bilirubin ≤1.5 x upper limit of normal (ULN) or ≤3 x ULN for patients with Gilbert's disease
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN, unless clearly due to disease involvement
Creatinine clearance ≥50 mL/min (calculated according to institutional standards or using Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formula)

Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug. Women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy. Men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
Patients or their legally authorized representative must provide written informed consent

Exclusion Criteria:

Patient is pregnant or breastfeeding
Patients with uncontrolled active infection
Hepatitis B or C infection, or known seropositivity for human immunodeficiency virus (HIV)
Major surgery or radiation therapy within 4 weeks prior to the first study dose
Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the exception of hydroxyurea, dexamethasone, or one dose of cytarabine) prior to starting therapy
No clinical, radiological or laboratory evidence of pancreatitis, including:
Serum lipase must be <2 times the ULN, and
Serum amylase must be <2 times the ULN
Symptomatic or untreated leptomeningeal disease or spinal cord compression. Patients with prior h/o CNS disease are eligible as long as no active CNS disease as documented by recent CSF analysis and/or imaging studies.
Patients with active heart disease [New York Heart Association (NYHA) class 3-4 as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last 6 months]
Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:

Myocardial infarction (MI), stroke, revascularization, unstable angina or transient ischemic attack within 6 months
Left ventricular ejection fraction (LVEF) less than 50%
Diagnosed or suspected congenital long QT syndrome
Clinically significant atrial or ventricular arrhythmias (such as uncontrolled, clinically significant atrial fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) as determined by the treating physician
Prolonged QTc interval on pre-entry electrocardiogram (> 480 msec) unless corrected after electrolyte replacement or Currently taking drugs that are known to have a risk of causing prolonged QTc or torsades de pointes (TdP) (unless these can be changed to acceptable alternatives or discontinued)
History of venous thromboembolism including deep venous thrombosis or pulmonary embolism within the past 3 months, excluding line-associated DVT of the upper extremity
Uncontrolled hypertension (diastolic blood pressure >100mmHg; systolic >150mmHg).

Uncontrolled hypertriglyceridemia (triglycerides > 450mg/dL)
History of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years. Patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses)
Taking any medications or herbal supplements that are known to be strong inhibitors (such as fluconazole, ketoconazole, voriconazole, and clarithromycin) or inducers (such as rifampin, rifabutin, phenytoin, carbamazepine, and St. John's Wort) of cytochrome P450 (CYP)3A4 within at least 7 days before the first dose of ponatinib or within 3 days of starting venetoclax.
Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 3 days prior to starting venetoclax
Malabsorption syndrome or other conditions that preclude enteral route of administration
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study